Histamine Signals Through H1 Receptors to Steer Microglia in Tic-Like Behavior Study

Tic disorders, marked by sudden, repetitive motor movements and vocalizations, affect a substantial share of children worldwide, yet the biological mechanisms that drive these involuntary behaviors remain stubbornly elusive. A new study published in BMC Neuroscience now points to an unexpected player in this puzzle: histamine, the molecule better known for its role in allergic reactions and gastric acid secretion, working in concert with its H1 receptor to shape the behavior of microglia, the brain’s resident immune cells. The research, led by Duan Lin, Yajun Tang, Qinyu Li, Yanting Lu, Jiqiang Xie, and Xiumei Liu at Fujian Medical University and collaborating institutions, offers fresh evidence that a neuroimmune signaling pathway may sit at the intersection of tic-like behaviors and brain inflammation.

The team turned to a well-established animal model in which mice are treated with β,β′-iminodipropionitrile, commonly abbreviated IDPN. This compound, when administered systemically, reliably produces stereotyped, repetitive movements in rodents that closely mirror the phenomenology of human tics. Researchers have used the IDPN model for decades to probe the basal ganglia circuits and neurotransmitter systems implicated in movement disorders, but the contribution of histaminergic signaling and neuroinflammation to the phenotype had not been fully characterized. The new work set out to fill that gap by measuring histamine dynamics, receptor expression, and microglial activation in the brains of IDPN-treated animals.

The first key finding concerned the hypothalamus, the brain region that contains the majority of the brain’s histamine-producing neurons. When the researchers quantified histamine levels and H1 receptor expression in this region, they found that both were significantly reduced in IDPN-treated mice compared with controls. This depletion of the central histaminergic tone is notable because histamine released from the tuberomammillary nucleus of the hypothalamus projects widely across the brain, influencing arousal, motor control, and immune signaling. A deficit in this system, the authors suggest, could plausibly disturb the circuit balance that governs the initiation and suppression of movements, creating conditions favorable to the emergence of tic-like stereotypies.

To test whether the loss of H1 receptor signaling is not merely a correlate but a potential driver of the behavior, the investigators administered diphenhydramine, a classic first-generation antihistamine that readily crosses the blood-brain barrier and blocks the H1 receptor. When wild-type mice, animals with no prior IDPN exposure, received intraperitoneal injections of diphenhydramine, they began to display tic-like stereotyped behaviors of their own. This pharmacological mimicry is a striking result: simply silencing H1 receptor signaling in otherwise healthy brains was sufficient to elicit a behavioral phenotype resembling that produced by IDPN. The observation aligns with clinical reports that have associated exposure to H1 receptor antagonists with increased risk and severity of tic disorders in children, lending translational weight to the animal data.

The second half of the study shifted focus to the striatum, a key component of the basal ganglia motor circuitry and a region long implicated in tic pathophysiology. In the IDPN-treated mice, the researchers observed increased immunoreactivity for Iba-1, a calcium-binding protein expressed specifically in microglia and macrophages that serves as a standard marker of microglial activation. Elevated Iba-1 staining indicates that the resident immune cells of the striatum had shifted into a reactive state, a phenomenon often associated with neuroinflammatory processes. Because microglia are the central phagocytic and immune-surveying cells of the central nervous system, their reactivity can influence synaptic pruning, neuronal excitability, and circuit function, all of which are plausible mechanistic links to abnormal movement patterns.

Having established that microglial reactivity accompanies the tic-like phenotype, the team then asked whether boosting histamine signaling in the striatum could reverse it. They performed intrastriatal injections of histamine directly into the brains of IDPN-treated mice. The result was twofold: the animals showed a reduction in their stereotyped behaviors, and the heightened Iba-1 immunoreactivity in the striatum was attenuated. In other words, replenishing histamine locally appeared to calm both the behavior and the immune activation simultaneously. This parallel effect strengthens the hypothesis that the behavioral and neuroimmune changes are mechanistically connected rather than independent byproducts of the IDPN treatment.

Crucially, the protective effect of histamine was not absolute. When the mice were pretreated with diphenhydramine before receiving the intrastriatal histamine, both the behavioral improvement and the reduction in microglial reactivity were blunted. This antagonist-attenuation experiment provides the strongest causal inference available within the study’s design: the benefits of histamine appear to depend on intact H1 receptor signaling, since blocking the receptor abolished the effect. Taken together, the data sketch a coherent pathway in which histamine acts through H1 receptors to restrain microglial reactivity in the striatum, and disruption of this signaling, whether by IDPN-induced depletion or by pharmacological antagonism, promotes tic-like stereotypies.

The authors are careful to frame their conclusions with appropriate scientific caution. Because the study relied on a pharmacological antagonist approach rather than genetic manipulation of the H1 receptor, and because it did not include microglia-specific interventions such as conditional knockout or depletion strategies, the findings should be interpreted as hypothesis-generating rather than definitive proof of mechanism. Diphenhydramine has pharmacological actions beyond H1 receptor blockade, including anticholinergic effects, and systemic administration cannot exclude contributions from peripheral immune signaling. Nonetheless, the convergence of multiple lines of evidence, reduced hypothalamic histamine and H1R in the model, induction of tic-like behavior by antagonist in wild-type animals, and rescue of both behavior and microglial activation by striatal histamine that is reversed by antagonist pretreatment, forms a compelling pattern.

The clinical implications are intriguing but require careful handling. Antihistamines are among the most widely used medications in pediatric populations, found in allergy remedies, cold preparations, and sleep aids. If H1 receptor blockade indeed exacerbates tic vulnerability, as both this animal work and prior clinical associations suggest, it may prompt clinicians to weigh tic risk more deliberately when prescribing brain-penetrant first-generation antihistamines to children, particularly those with a family history or early signs of tic disorders. Conversely, strategies that enhance central histaminergic tone or support H1 receptor signaling could represent a novel therapeutic direction, though any such approach would need to navigate histamine’s broad involvement in sleep, appetite, cognition, and other physiological functions.

Beyond tics, the study contributes to a rapidly growing appreciation of neuroimmunology in developmental neuropsychiatric conditions. Microglial reactivity has been implicated in conditions ranging from autism spectrum disorder to obsessive-compulsive disorder, conditions that share phenomenological and neurobiological overlap with tic disorders. The idea that a classical neurotransmitter system like histamine can serve as a modulatory bridge between neuronal circuits and glial immune responses opens a conceptual avenue that extends well beyond a single disease. The work was supported by the Joint Funds for the Innovation of Science and Technology of Fujian Province and the Fujian Provincial Natural Science Foundation of China, and all animal experiments were approved by the Experimental Animal Ethics Committee of Fujian Medical University. As the field moves forward, genetic models and microglia-specific tools will be essential to confirm whether the histamine-H1R-microglia axis can be safely and effectively targeted to help patients whose lives are disrupted by persistent tics.

Subject of Research: Histamine-H1 receptor regulation of microglial reactivity in an IDPN-induced mouse model of tic-like behaviors

Article Title: Histamine and H1R regulate microglia in an IDPN-Induced Mouse Model of Tic-like behaviors

Article References: Lin, D., Tang, Y., Li, Q., Lu, Y., Xie, J., & Liu, X. (2026). Histamine and H1R regulate microglia in an IDPN-Induced Mouse Model of Tic-like behaviors. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01039-w

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01039-w

Keywords: tic disorder, histamine, H1 receptor, microglia, IDPN, diphenhydramine, neuroinflammation, striatum, basal ganglia, hypothalamus, neuroimmunology, movement disorders